“神药”又未获批，已停工停产、多地断货，价格曾疯涨至5000元/盒

Core Viewpoint - The article discusses the ongoing challenges faced by Green Valley Pharmaceutical regarding its Alzheimer's drug GV-971 (甘露特钠胶囊), which has not received re-registration approval, leading to potential production halts and supply shortages [4][21]. Group 1: Drug Approval and Market Status - GV-971, developed for mild to moderate Alzheimer's disease, was conditionally approved in November 2019, marking the first new Alzheimer's drug approval in 17 years [8]. - The drug has faced significant scrutiny regarding its efficacy and clinical trial data, with notable public disputes among experts [8][9]. - As of May 2023, reports indicated nationwide shortages of GV-971, with prices on e-commerce platforms soaring to 5000 yuan per box, compared to its original price of 296 yuan when included in medical insurance [20]. Group 2: Production and Regulatory Challenges - Green Valley announced in May 2023 that it would halt production of GV-971 due to the expiration of its drug registration certificate, which is typically renewed six months prior to expiration [20][21]. - The failure to secure re-registration approval is believed to be linked to poor clinical trial data or unclear efficacy [21]. - The company has faced criticism for its handling of the drug's international clinical trials, which were suspended in May 2022 [8][9]. Group 3: Patient Impact and Alternatives - Patients have expressed concerns over the potential impact of drug shortages, but experts suggest that the drug's mechanism does not lead to immediate adverse effects upon discontinuation [21]. - Alternatives for patients include symptom-targeting medications and non-pharmacological interventions, although no similar mechanism drugs have been approved [21].